Biomark Diagnostics Inc. (FRA:20B)
Germany · Delayed Price · Currency is EUR 0.2000
+0.0010 (0.50%)
At close: Nov 27, 2025
Biomark Diagnostics Company Description
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer.
The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer.
It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers.
The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Biomark Diagnostics Inc.
| Country | Canada |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Rashid Ahmed Bux |
Contact Details
Address: 3851 Shell Road Richmond, British Columbia V6X 2W2 Canada | |
| Phone | 604 370 0779 |
| Website | biomarkdiagnostics.com |
Stock Details
| Ticker Symbol | 20B |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Rashid Ahmed Bux | Chief Executive Officer |
| Guoyu Huang | Chief Financial Officer |